Aerosolized antibiotics for non-cystic fibrosis bronchiectasis

Respiration

Volumn 88, Issue 3, 2014, Pages 177-184

  Rubin, Bruce K ^a   Williams, Ronald W ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aerosols; Antibiotic resistance; Bronchiectasis; Cystic fibrosis

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CIPROFLOXACIN; COLISTIN; GENTAMICIN; LEVOFLOXACIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

AEROSOL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL LOAD; BRONCHIECTASIS; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL (TOPIC); DRUG TOLERABILITY; HUMAN; MEDICAL NEBULIZER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYMPTOMATOLOGY; SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; COMPLICATION; HAEMOPHILUS INFECTIONS; INHALATIONAL DRUG ADMINISTRATION; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCOCCAL; PSEUDOMONAS INFECTIONS;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; HAEMOPHILUS INFECTIONS; HUMANS; PNEUMONIA, BACTERIAL; PNEUMONIA, PNEUMOCOCCAL; PSEUDOMONAS INFECTIONS; QUALITY OF LIFE;

EID: 84906643002     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000366000     Document Type: Review

References (78)

1. Goeminne P, Dupont L: Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century. Postgrad Med J 2010; 86: 493-501.
2. Cohen M, Sahn SA: Bronchiectasis in systemic diseases. Chest 1999; 116: 1063-1074.
3. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, et al: An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162: 1277-1284.
4. Fuschillo S, De Felice A, Balzano G: Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J 2008; 31: 396-406.
5. De Soyza A, Brown JS, Loebinger MR; Bronchiectasis Research and Academic Network: Research priorities in bronchiectasis. Thorax 2013; 68: 695-696.
6. Short-and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012; 186: 657-665.
7. Metersky ML, O'Donnell AE: Nebulized colistin for non-cystic fibrosis bronchiectasis: déjà vu all over again? Am J Respir Crit Care Med 2014; 189: 1151-1152.
8. Wills PJ, Wodehouse T, Corkery K, Mallon K, Wilson R, Cole PJ: Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability. Am J Respir Crit Care Med 1996; 154: 413-417.
9. O'Donnell AE, Barker AF, Ilowite JS, Fick RB: Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998; 113: 1329-1334.
10. Serisier DJ: The evidence base for non-CF bronchiectasis is finally evolving. Respirology 2014; 19: 295-297.
11. Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, et al: Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162: 481-485.
12. Feldman C: Bronchiectasis: new approaches to diagnosis and management. Clin Chest Med 2011; 32: 535-546.
13. McShane PJ, Naureckas ET, Tino G, Strek ME: Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2013; 188: 647-656.
14. Amorim A, Gamboa F, Azevedo P: New advances in the therapy of non-cystic fibrosis bronchiectasis. Rev Port Pneumol 2013; 19: 266-275.
15. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al: Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331: 637-642.
16. Vendrell M, de Gracia J, Olveira C, Martínez MA, Girón R, Máiz L, et al: Diagnosis and treatment of bronchiectasis. Spanish Society of Pneumology and Thoracic Surgery. Arch Bronconeumol 2008; 44: 629-640.
17. Serisier DJ, Bilton D, De Soyza A, Thompson PJ, Kolbe J, Greville HW, et al: Inhaled, dualrelease liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013; 68: 812-817.
18. Kapur N, Masters IB, Morris PS, Galligan J, Ware R, Chang AB: Defining pulmonary exacerbation in children with non-cystic fibrosis bronchiectasis. Pediatr Pulmonol 2012; 47: 68-75.
19. Cole PJ: Inflammation: a two-edged sword-the model of bronchiectasis. Eur J Respir Dis Suppl 1986; 147: 6-15.
20. Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D: Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014; 189: 975-982.
21. Angrill J, Agustí C, de Celis R, Filella X, Rañó A, Elena M, et al: Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001; 164: 1628-1632.
22. Kapur N, Grimwood K, Masters IB, Morris PS, Chang AB: Lower airway microbiology and cellularity in children with newly diagnosed non-CF bronchiectasis. Pediatr Pulmonol 2012; 47: 300-307.
23. Chang AB, Bilton D: Exacerbations in cystic fibrosis. 4. Non-cystic fibrosis bronchiectasis. Thorax 2008; 63: 269-276.
24. Rogers GB, van der Gast CJ, Cuthbertson L, Thomson SK, Bruce KD, Martin ML, et al: Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax 2013; 68: 731-737.
25. Seitz AE, Olivier KN, Steiner CA, Montes de Oca R, Holland SM, Prevots DR: Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest 2010; 138: 944-949.
26. Rubin BK: Did Lady Windermere have cystic fibrosis? Chest 2006; 130: 937-938.
27. Sexton P, Harrison AC: Susceptibility to nontuberculous mycobacterial lung disease. Eur Respir J 2008; 31: 1322-1333.
28. Rademacher J, Welte T: Bronchiectasis-diagnosis and treatment. Dtsch Ärztebl Int 2011; 108: 809-815.
29. Martínez-García MÁ, Soler Cataluña JJ, Perpiñá-Tordera M, Román-Sánchez P, Soriano J: Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007; 132: 1565-1572.
30. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW: Microbiologic followup study in adult bronchiectasis. Respir Med 2007; 101: 1633-1638.
31. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al: Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380: 660-667.
32. Evans DJ, Greenstone M: Long-term antibiotics in the management of non-CF bronchiectasis-do they improve outcome? Respir Med 2003; 97: 851-858.
33. Rubin BK: Aerosolized antibiotics for noncystic fibrosis bronchiectasis. J Aerosol Med Pulm D 2008; 21: 71-76.
34. Martínez-García MÁ, Máiz Carro L, Catalán-Serra P: Treatment of non-cystic fibrosis bronchiectasis. Archiv Bronconeumol 2011; 47: 599-609.
35. Hanif SNM, Garcia-Contreras L: Pharmaceutical aerosols for the treatment and prevention of tuberculosis. Front Cell Infect Microbiol 2012; 2: 118.
36. Nikander K, Prince I, Coughlin S, Warren S, Taylor G: Mode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) System affects lung deposition of 99mTc-DTPA. J Aerosol Med Pulm D 2010; 23:S-37-S-43.
37. Morosini MI, García-Castillo M, Loza E, Pérez-Vázquez M, Baquero F, Cantón R: Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips. J Clin Microbiol 2005; 43: 4480-4485.
38. Couch LA: Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest 2001; 120: 114S-117S.
39. Drobnic ME: Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2004; 39: 39-44.
40. Bilton D, Henig N, Morrissey B, Gotfried M: Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006; 130: 1503-1510.
41. Scheinberg P, Shore E: A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005; 127: 1420-1426.
42. Barker A, O'Donnell A, Thompson P, et al: Two phase 3 placebo-controlled trials of aztreonam lysine for inhalation (AZLI) for noncystic fibrosis bronchiectasis (NCFB). Eur Respir J 2013; 42(suppl 57):4136.
43. Michalopoulos A, Papadakis E: Inhaled antiinfective agents: emphasis on colistin. Infection 2010; 38: 81-88.
44. Steinfort DP, Steinfort C: Effect of long-term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J 2007; 37: 495-498.
45. Dhar R, Anwar GA, Bourke SC, Doherty L, Middleton P, Ward C, et al: Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa. Thorax 2010; 65: 553-553.
46. Murray MP, Govan JRW, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, et al: A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011; 183: 491-499.
47. Pecota N: Aradigm reports successful ORBIT-1 bronchiectasis study with inhaled liposomal ciprofloxacin. http://investor.aradigm.com/releasedetail.cfm (accessed 17 May 2014).
48. Aradigm Corporation, Grifols Therapeutics Inc: Phase 3 study with dual-release ciprofloxacin for inhalation in non-CF bronchiectasis. http://clinicaltrials.gov/ct2/show/study/NCT01515007 (accessed 26 May 2014).
49. Aradigm Corporation, Grifols Therapeutics Inc: Phase 3 study with pulmaquin in non-CF bronchiectasis (ORBIT-4). http://clinicaltrials. gov/ct2/show/study/NCT02104245 (accessed 26, May 2014).
50. Wilson R, Welte T, Polverino E, De Soyza A, Greville H, O'Donnell A, et al: Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013; 41: 1107-1115.
51. Bayer, Novartis: Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis (non-CF BE) (RESPIRE 1). http://clinicaltrials. gov/ct2/show/NCT01764841 (accessed 17, May 2014)
52. Bayer, Novartis: Ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (non-CF BE) (RESPIRE 2). http://clinicaltrials.gov/ct2/show/NCT02106 832?term=NCT02106832&rank=1 (accessed 17 May 2014)
53. Bayer: FDA grants orphan drug designation for Bayer's investigational ciprofloxacin DPI (dry powder for inhalation) for treatment of non-cystic fibrosis bronchiectasis. Bayer Healthcare 2014, http://www.pharma.bayer. com/html/pdf/Final-FDA-Grants-Orphan- Drug-Designation-for-Investigational-Ciprofloxacin- DPI.pdf.
54. Manzanedo D, Brande M, Kramer S, et al: Formulation characterization of a novel levofloxacin pulmonary dry powder drug delivery technology. Respiratory Drug Delivery Conference, Phoenix, 2012, pp 1-4.
55. Qilu Hospital: Combined administration of nebulized amikacin in patients with acute exacerbation of non-cystic fibrosis bronchiectasis. http://clinicaltrials.gov/ct2/show/study/NCT02081963 (accessed 17 May 2014).
56. Huang CT, Stewart PS: Reduction of polysaccharide production in Pseudomonas aeruginosa biofilms by bismuth dimercaprol (Bis-BAL) treatment. J Antimicrob Chemother 1999; 44: 601-605.
57. Halwani M, Blomme S, Suntres ZE, Alipour M, Azghani AO, Kumar A, et al: Liposomal bismuth-ethanedithiol formulation enhances antimicrobial activity of tobramycin. Int J Pharmaceut 2008; 358: 278-284.
58. Halwani M, Hebert S, Suntres ZE, Lafrenie RM, Azghani AO, Omri A: Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum-sensing molecules production by Pseudomonas aeruginosa. Int J Pharmaceut 2009; 373: 141-146.
59. Alipour M, Suntres ZE, Lafrenie RM, Omri A: Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by co-encapsulation of bismuth-ethanedithiol with tobramycin in liposomes. J Antimicrob Chemother 2010; 65: 684-693.
60. Alhariri M, Omri A: Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection. Antimicrob Agents Chemother 2013; 57: 569-578.
61. Kaneko Y, Thoendel M, Olakanmi O, Britigan BE, Singh PK: The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J Clin Invest 2007; 117: 877-888.
62. Halwani M, Yebio B, Suntres ZE, Alipour M, Azghani AO, Omri A: Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa. J Antimicrob Chemother 2008; 62: 1291-1297.
63. Alhajlan M, Alhariri M, Omri A: Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. Antimicrob Agents Chemother 2013; 57: 2694-2704.
64. Chono S, Suzuki H, Togami K, Morimoto K: Efficient drug delivery to lung epithelial lining fluid by aerosolization of ciprofloxacin incorporated into PEGylated liposomes for treatment of respiratory infections. Drug Dev Ind Pharm 2011; 37: 367-372.
65. MacLeod DL, Barker LM, Sutherland JL, Moss SC, Gurgel JL, Kenney TF, et al: Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 2009; 64: 829-836.
66. McCaughey G, McKevitt M, Elborn JS, Tunney MM: Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions. J Cyst Fibros 2012; 11: 163-172.
67. Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M, et al: Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection. Am J Respir Crit Care Med 2012; 185: 171-178.
68. Anderson GG, Kenney TF, MacLeod DL, Henig NR, O'Toole GA: Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination. Pathog Dis 2013; 67: 39-45.
69. Montgomery AB, Vallance S, Abuan T, Tservistas M, Davies A: A Randomized doubleblind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI Investigational eFlow ® Inline Nebulizer System in mechanically ventilated patients. J Aerosol Med Pulm Drug Deliv 2014; 27: 1-8.
70. Herrmann G, Yang L, Wu H, Song Z, Wang H, Høiby N, et al: Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J Infect Dis 2010; 202: 1585-1592.
71. Dudley MN, Loutit J, Griffith DC: Aerosol antibiotics: considerations in pharmacological and clinical evaluation. Curr Opin Biotechnol 2008; 19: 637-643.
72. Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michalopoulos A: Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis 2005; 5: 24.
73. Delissalde F, Amábile-Cuevas CF: Comparison of antibiotic susceptibility and plasmid content, between biofilm producing and nonproducing clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents 2004; 24: 405-408.
74. Ryan G, Singh M, Dwan K: Inhaled antibiotics for long-term therapy in cystic fibrosis (review). Cochrane Database Syst Rev 2011; CD001021.
75. Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, McKevitt M, Montgomery AB: Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). J Antimicrob Chemother 2011; 66: 2398-2404.
76. Conway DSP, Brownlee KG, Denton M, Peckham DG: Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Am J Respir Med 2003; 2: 321-332.
77. Conway DS: Nebulized antibiotic therapy: the evidence. Chron Respir Dis 2005; 2: 35-41.
78. Hunt BE, Weber A, Berger A, Ramsey B, Smith AL: Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob Agents Chemother 1995; 39: 34-39.